Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF -1-
July 9, 2001
- Pharmacia Enhances R&D Organization in Japan
July 9, 2001
- Shareholders' Meetings Last Longer Due to Increasing Number of Questions
July 9, 2001
- Superiority of Singulaire over Pranlukast Verified: Banyu Symposium
July 9, 2001
- Gap Between NHI Prices and Market Prices Widening to about 7%
July 9, 2001
- Package Insert Drafting Guidebook for Medical Devices Issued
July 9, 2001
- Kasamatsu Meiki, Hokuho Iyaku Tie Up in Hokuriku
July 9, 2001
- Rocornal Has Secondary Preventive Effects on CAD: J-MIC (M) Study
July 9, 2001
- Contract MRs to Increase from 1,500 to 2,600 Next Year: Quintiles Seminar
July 9, 2001
- Daiichi to Apply for Prevention of Recurrent Stroke for Coversyl
July 9, 2001
- Yutaka Pharmacy Acquires Local Drugstores in Aichi
July 9, 2001
- Determination of Anti-acid-fast Bacteria Antibody Covered by Insurance
July 9, 2001
- REGULATORY NEWS IN BRIEF -2-
July 9, 2001
- 4,310 ADRs Reported by Monitor Pharmacies in Tokyo in 10 Years
July 9, 2001
- REGULATORY NEWS IN BRIEF -1-
July 9, 2001
- Japanese Makers' Globalization Discussed: Interphex Japan
July 9, 2001
- Safety Info. No. 267 Focuses on Reye Syndrome Due to Salicylate
July 9, 2001
- Yamanouchi Forms Alliance with Celera Genomics
July 9, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 9, 2001
- JPMA to Propose New Drug Benefit System: Mr Nagayama
July 9, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…